GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Interest Coverage

LakeShore Biopharma Co (LakeShore Biopharma Co) Interest Coverage : 0 (At Loss) (As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. LakeShore Biopharma Co's Operating Income for the six months ended in Sep. 2023 was $-23.11 Mil. LakeShore Biopharma Co's Interest Expense for the six months ended in Sep. 2023 was $-2.05 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for LakeShore Biopharma Co's Interest Coverage or its related term are showing as below:


LSB's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 148.11
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


LakeShore Biopharma Co Interest Coverage Historical Data

The historical data trend for LakeShore Biopharma Co's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

LakeShore Biopharma Co Interest Coverage Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
Interest Coverage
- - -

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Interest Coverage Get a 7-Day Free Trial - - 0.30 - -

Competitive Comparison of LakeShore Biopharma Co's Interest Coverage

For the Biotechnology subindustry, LakeShore Biopharma Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LakeShore Biopharma Co's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Interest Coverage distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Interest Coverage falls into.



LakeShore Biopharma Co Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LakeShore Biopharma Co's Interest Coverage for the fiscal year that ended in Mar. 2023 is calculated as

Here, for the fiscal year that ended in Mar. 2023, LakeShore Biopharma Co's Interest Expense was $-4.48 Mil. Its Operating Income was $-16.44 Mil. And its Long-Term Debt & Capital Lease Obligation was $43.56 Mil.

LakeShore Biopharma Co did not have earnings to cover the interest expense.

LakeShore Biopharma Co's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Here, for the six months ended in Sep. 2023, LakeShore Biopharma Co's Interest Expense was $-2.05 Mil. Its Operating Income was $-23.11 Mil. And its Long-Term Debt & Capital Lease Obligation was $50.21 Mil.

LakeShore Biopharma Co did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


LakeShore Biopharma Co  (NAS:LSB) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


LakeShore Biopharma Co Interest Coverage Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.